| Literature DB >> 9789055 |
R Soiffer1, T Lynch, M Mihm, K Jung, C Rhuda, J C Schmollinger, F S Hodi, L Liebster, P Lam, S Mentzer, S Singer, K K Tanabe, A B Cosimi, R Duda, A Sober, A Bhan, J Daley, D Neuberg, G Parry, J Rokovich, L Richards, J Drayer, A Berns, S Clift, L K Cohen, R C Mulligan, G Dranoff.
Abstract
We conducted a Phase I clinical trial investigating the biologic activity of vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma. Immunization sites were intensely infiltrated with T lymphocytes, dendritic cells, macrophages, and eosinophils in all 21 evaluable patients. Although metastatic lesions resected before vaccination were minimally infiltrated with cells of the immune system in all patients, metastatic lesions resected after vaccination were densely infiltrated with T lymphocytes and plasma cells and showed extensive tumor destruction (at least 80%), fibrosis, and edema in 11 of 16 patients examined. Antimelanoma cytotoxic T cell and antibody responses were associated with tumor destruction. These results demonstrate that vaccination with irradiated autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor stimulates potent antitumor immunity in humans with metastatic melanoma.Entities:
Mesh：
Substances：
Year: 1998 PMID： 9789055 PMCID： PMC23738 DOI： 10.1073/pnas.95.22.13141
Source DB: PubMed Journal: Proc Natl Acad Sci U S A ISSN： 0027-8424 Impact factor: 11.205